Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells 804 Shares

Key Points

• Disc Medicine COO Jonathan Yen-Wen Yu sold 804 shares at an average price of $82.64, generating $66,442.56 and reducing his holdings by 1.46% to 54,324 shares. The sale follows several additional insider sales since mid-June.
• IRON shares traded at $78.84, down $1.17, with the stock positioned between its $40.00 one-year low and $99.50 high. Disc Medicine exceeded quarterly earnings expectations, reporting a loss of $1.54 per share versus the projected $1.71 loss.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $106.00 target price; institutional investors own 83.70% of the company.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) COO Jonathan Yen-Wen Yu sold 804 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $82.64, for a total value of $66,442.56. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at $4,489,335.36. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Price Performance

Shares of IRON traded down $1.17 during midday trading on Friday, hitting $78.84. The company's stock had a trading volume of 262,542 shares, compared to its average volume of 326,915. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The company's fifty day simple moving average is $74.60 and its two-hundred day simple moving average is $69.96. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $301.96 million, a price-to-earnings ratio of -11.98 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. As a group, equities analysts expect that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Disc Medicine by 22.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock valued at $756,000 after purchasing an additional 2,807 shares during the period. Millennium Management LLC raised its stake in Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company's stock worth $5,386,000 after buying an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock worth $4,793,000 after acquiring an additional 3,454 shares in the last quarter. Legal & General Group Plc grew its stake in Disc Medicine by 18.0% in the second quarter. Legal & General Group Plc now owns 24,097 shares of the company's stock valued at $1,276,000 after acquiring an additional 3,682 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Disc Medicine by 21.6% during the second quarter. Invesco Ltd. now owns 16,817 shares of the company's stock valued at $891,000 after acquiring an additional 2,983 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Morgan Stanley boosted their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an "overweight" rating in a report on Monday, June 15th. Wall Street Zen raised shares of Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. HC Wainwright lifted their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wedbush reaffirmed an "outperform" rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research note on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $106.00.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source